Advanced Search: Metastatic/Unresectable

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201601048

Phase 1 study evaluating combination therapy with the receptor tyrosine kinase inhibitor Pexidartinib (PLX3397) and Sirolimus in patients with unresectable sarcoma and Phase 2 study in malignant peripheral nerve sheath tumors.

201709159

A Phase III Study of AL3818 (Catequentinib,Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

201804065

A Multi-center Phase III, Randomized, Open-Label Trial of Vigil (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolimide as a Second-Line Regimen for Ewing’s Sarcoma

201904129

A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-Targeting Human Antibody-Cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-Line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

201904212

A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD 1 STUDY)

201905136

Protocol J1S-MC-JAAA CAMPFIRE: Childrens and Young Adult Master Protocol for Innovative Pediatric Research

201906040

A PHASE 1b STUDY OF PTC596 IN COMBINATION WITH DACARBAZINE IN PATIENTS WITH LOCALLY RECURRENT, UNRESECTABLE OR METASTATIC RELAPSED/REFRACTORY LEIOMYOSARCOMA

201907126

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

202006030

Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor

202008172

: NCI Protocol 10330, A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma